8-KLeadership ChangesExhibits & Filings

DEXCOM INC 8-K Report, Executive Changes (Jun 22, 2010)

Filed June 22, 2010For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on June 22, 2010, to announce significant executive leadership changes. The company promoted Steven R. Pacelli to the newly created position of Chief Operating Officer (COO) and Jorge Valdes to the newly created position of Chief Technical Officer (CTO). These promotions reflect a strategic expansion of the company's executive team to enhance operational and technical leadership as DexCom continues to grow its business. Mr. Pacelli, formerly Chief Administrative Officer, will now oversee a broad range of commercial functions, including sales, marketing, finance, and investor relations. Mr. Valdes, previously Senior Vice President of Operations, will lead research and development, manufacturing, and IT. Both executives received increases in their base salaries to $270,000 and a target bonus opportunity of 70% of their base salary, reflecting their expanded responsibilities and contributions to the company.

Key Highlights

  • 1DexCom appointed Steven R. Pacelli as Chief Operating Officer (COO), a new role.
  • 2DexCom appointed Jorge Valdes as Chief Technical Officer (CTO), also a new role.
  • 3Mr. Pacelli's responsibilities will include strategic and operational leadership of sales, marketing, finance, and other commercial functions.
  • 4Mr. Valdes' responsibilities will encompass research and development, manufacturing, and information technology.
  • 5Both promoted executives received a base salary increase to $270,000.
  • 6Both executives have a target bonus opportunity of 70% of their annual base salary.
  • 7The press release announcing these changes is included as an exhibit to the filing.

Frequently Asked Questions

This 8-K filing announces significant executive leadership changes at DexCom, Inc. Specifically, it details the promotion of two key individuals, Steven R. Pacelli to Chief Operating Officer and Jorge Valdes to Chief Technical Officer, into newly created positions.

As COO, Mr. Pacelli is responsible for the strategic and operational leadership of DexCom's sales, marketing, finance, customer support, quality, corporate development, managed care, human resources, legal, intellectual property, and investor relations functions.

As CTO, Mr. Valdes is responsible for the strategic and operational leadership of DexCom's research and development function, including clinical and regulatory affairs, as well as information technology and manufacturing operations.

In connection with their promotions, both Mr. Pacelli and Mr. Valdes received an increase in their annual base salary to $270,000 and a target bonus amount of 70% of their annual base salary, as approved by the Compensation Committee of the Board of Directors.